Modeling conformational transitions in kinases by molecular dynamics simulations: Achievements, difficulties, and open challenges

Frontiers in Genetics

Volumn 5, Issue MAY, 2014, Pages 1-

  D'Abramo, Marco ^a,b   Besker, Neva ^c   Chillemi, Giovanni ^a   Grottesi, Alessandro ^a  

^a CINECA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Computational modeling; Conformational pathways; Conformational transitions; Kinases; Molecular dynamics

Indexed keywords

EID: 84905658166     PISSN: None     EISSN: 16648021     Source Type: Journal    
DOI: 10.3389/fgene.2014.00128     Document Type: Short Survey

References (33)

1. Albaugh, P., Fan, Y., Mi, Y., Sun, F., Adrian, F., Li, N., et al. (2012). Discovery of GNF-5837, a Selective TRK Inhibitor with efficacy in rodent cancer tumor models. ACS Med. Chem. Lett. 3, 140-145. doi: 10.1021/ml200261d
2. Ban, D., Funk, M., Gulich, R., Egger, D., Sabo, T. M., Walter, K. F. A., et al. (2011). Kinetics of conformational sampling in ubiquitin. Angew. Chem. Int. Ed. 50, 11437-11440. doi: 10.1002/anie.201105086
3. Beckstein, O., Denning, E. J., Perilla, J. R., and Woolf, T. B. (2009). Zipping and unzipping of adenylate kinase: atomistic insights into the ensemble of open <-> closed transitions. J. Mol. Biol. 394, 160-176. doi: 10.1016/j.jmb.2009.09.009
4. Bešker, N., Amadei, A., and D'Abramo, M. (2013). Molecular mechanisms of activation in CDK2. J. Biomol. Struct. Dyn. doi: 10.1080/07391102.2013.844080. [Epub ahead of print].
5. Braig, S., Kressirer, C. A., Liebl, J., Bischoff, F., Zahler, S., Meijer, L., et al. (2013). Indirubin derivative 6BIO suppresses metastasis. Cancer Res. 73, 6004-6012. doi: 10.1158/0008-5472.CAN-12-4358
6. Dardick, C., and Ronald, P. (2006). Plant and animal pathogen recognition receptors signal through non-RD kinases. PLoPathog. 2:e2. doi: 10.1371/journal.ppat.0020002
7. Debondt, H. L., Rosenblatt, J., Jancarik, J., Jones, H. D., Morgan, D. O., and Kim, S. H. (1993). Crystal-structure of cyclin-dependent kinase-2. Nature 363, 595-602. doi: 10.1038/363595a0
8. Endicott, J. A., Noble, M. E. M., and Johnson, L. N. (2012). The structural basis for control of eukaryotic protein kinases. Annu. Rev. Biochem. 81, 587-613. doi: 10.1146/annurev-biochem-052410-090317
9. Fernandez, A., Sanguino, A., Peng, Z., Ozturk, E., Chen, J., Crespo, A., et al. (2007). An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic. J. Clin. Invest. 117, 4044-4054. doi: 10.1172/JCI32373
10. Hantschel, O., and Superti-Furga, G. (2004). Regulation of the C-Abl and Bcr-Abl tyrosine kinases. Nat. Rev. Mol. Cell Biol. 5, 33-44. doi: 10.1038/nrm1280
11. Huang, H., Ozkirimli, E., and Post, C. B. (2009). Comparison of three perturbation molecular dynamics methods for modeling conformational transitions. J. Chem. Theory Comput. 5, 1304-1314. doi: 10.1021/ct9000153
12. Huang, H., Zhao, R., Dickson, B. M., Skeel, R. D., and Post, C. B. (2012). alpha C Helix as a Switch in the conformational transition of Src/CDK-like kinase domains. J. Phys. Chem. B 116, 4465-4475. doi: 10.1021/jp301628r
13. Huse, M., and Kuriyan, J. (2002). The conformational plasticity of protein kinases. Cell 109, 275-282. doi: 10.1016/S0092-8674(02)00741-9
14. Kornev, A. P., Haste, N. M., Taylor, S. S., and Ten Eyck, L. F. (2006). Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism. Proc. Natl. Acad. Sci. U.S.A. 103, 17783-17788. doi: 10.1073/pnas.0607656103
15. Kornev, A. P., and Taylor, S. S. (2010). Defining the conserved internal architecture of a protein kinase. Biochim. Biophys. Acta 1804, 440-444. doi: 10.1016/j.bbapap.2009.10.017
16. Kornev, A. P., Taylor, S. S., and Ten Eyck, L. F. (2008). A helix scaffold for the assembly of active protein kinases. Proc. Natl. Acad. Sci. U.S.A. 105, 14377-14382. doi: 10.1073/pnas.0807988105
17. Kumar, A., Chaturvedi, V., Bhatnagar, S., Sinha, S., and Siddiqi, M. I. (2009). Knowledge based identification of potent antitubercular compounds using structure based virtual screening and structure interaction fingerprints. J. Chem. Inf. Model. 49, 35-42. doi: 10.1021/ci8003607
18. Lambert, G. K., Duhme-Klair, A. K., Morgan, T., and Ramjee, M. K. (2013). The background, discovery and clinical development of BCR-ABL inhibitors. Drug Discov. Today 18, 992-1000. doi: 10.1016/j.drudis.2013.06.001
19. Lapenna, S., and Giordano, A. (2009). Cell cycle kinases as therapeutic targets for cancer. Nat. Rev. Drug Discov. 8, 547-566. doi: 10.1038/nrd2907
20. Levinson, N. M., Kuchment, O., Shen, K., Young, M. A., Koldobskiy, M., Karplus, M., et al. (2006). A Src-like inactive conformation in the Abl tyrosine kinase domain. PLoS Biol. 4:e144. doi: 10.1371/journal.pbio.0040144
21. Lolli, G. (2010). Structural dissection of cyclin dependent kinases regulation and protein recognition properties. Cell Cycle 9, 1551-1561. doi: 10.4161/cc.9.8.11195
22. Lowe, E. D., Noble, M. E. M., Skamnaki, V. T., Oikonomakos, N. G., Owen, D. J., and Johnson, L. N. (1997). The crystal structure of a phosphorylase kinase peptide substrate complex: kinase substrate recognition. Embo. J. 16, 6646-6658. doi: 10.1093/emboj/16.22.6646
23. Madhusudan, P. A., Xuong, N. H., and Taylor, S. S. (2002). Crystal structure of a transition state mimic of the catalytic subunit of cAMP-dependent protein kinase. Nat. Struct. Biol. 9, 273-277. doi: 10.1038/nsb780
24. Noble, M. E. M., Endicott, J. A., and Johnson, L. N. (2004). Protein kinase inhibitors: Insights into drug design from structure. Science 303, 1800-1805. doi: 10.1126/science.1095920
25. Nolen, B., Taylor, S., and Ghosh, G. (2004). Regulation of protein kinases: controlling activity through activation segment conformation. Mol. Cell 15, 661-675. doi: 10.1016/j.molcel.2004.08.024
26. Shan, Y., Arkhipov, A., Kim, E. T., Pan, A. C., and Shaw, D. E. (2013). Transitions to catalytically inactive conformations in EGFR kinase. Proc. Natl. Acad. Sci. U.S.A. 110, 7270-7275. doi: 10.1073/pnas.1220843110
27. Shan, Y., Seeliger, M. A., Eastwood, M. P., Frank, F., Xu, H., Jensen, M. O., et al. (2009). A conserved protonation-dependent switch controls drug binding in the Abl kinase. Proc. Natl. Acad. Sci. U.S.A. 106, 139-144. doi: 10.1073/pnas.0811223106
28. Sicheri, F., Moarefi, I., and Kuriyan, J. (1997). Crystal structure of the Src family tyrosine kinase Hck. Nature 385, 602-609. doi: 10.1038/385602a0
29. Waldrop, M. M. (2014). The big guns. Nature 505, 604-606. doi: 10.1038/505604a
30. Wermuth, G., Ganellin, C. R., Lindberg, P., and Mitscher, L. A. (1998). Glossary of terms used in medicinal chemistry (IUPAC Recommendations 1998). Pure Appl. Chem. 70, 1129-1143. doi: 10.1351/pac199870051129
31. Xu, W. Q., Harrison, S. C., and Eck, M. J. (1997). Three-dimensional structure of the tyrosine kinase c-Src. Nature 385, 595-602. doi: 10.1038/385595a0
32. Yang, S., Banavali, N. K., and Roux, B. (2009). Mapping the conformational transition in Src activation by cumulating the information from multiple molecular dynamics trajectories. Proc. Natl. Acad. Sci. U.S.A. 106, 3776-3781. doi: 10.1073/pnas.0808261106
33. Zahler, S., Tietze, S., Totzke, F., Kubbutat, M., Meijer, L., Vollmar, A. M., et al. (2007). Inverse in silico screening for identification of kinase inhibitor targets. Chem. Biol. 14, 1207-1214. doi: 10.1016/j.chembiol.2007.10.010